Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea

New England Journal of Medicine

Volumn 322, Issue 15, 1990, Pages 1037-1045

  Rodgers, Griffin P ^a   Dover, George J ^c   Noguchi, Constance Tom ^a   Schechter, Alan N ^a   Nienhuis, Arthur W ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; RADIOISOTOPE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; FEMALE; HEREDITY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

ADULT; ANEMIA, SICKLE CELL; BLOOD CELL COUNT; BONE MARROW; FEMALE; FETAL HEMOGLOBIN; HEMATOPOIESIS; HEMOGLOBIN, SICKLE; HEMOGLOBINS; HUMAN; HYDROXYUREA; MALE; POLYMERS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025217816     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199004123221504     Document Type: Article

References (33)

1. DeSimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A 1982; 79: 4428–31.
2. Ley TJ, DeSimone J, Anagnou NP, et al. 5-Azacytidine selectively increases γ-globin synthesis in a patient with β+ thalassemia. N Engl J Med 1982; 307: 1469–75.
3. Ley TJ, DeSimone J, Noguchi CT, et al. 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983; 62: 370–80.
4. Charache S, Dover G, Smith K, Talbot CC Jr, Moyer M, Boyer S. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci U S A 1983; 80: 4842–6.
5. Shinar E, Shalev O, Rachmilewitz EA. Schrier SL. Erythrocyte membrane skeleton abnormalities in severe β-thalassemia. Blood 1987; 70: 158–64.
6. Schechter AN. Noguchi CT, Rodgers GP. Sickle cell anemia. In: Stamatoyannopoulos G, Nienhuis AW, Leder P, Majerus PW. eds. The molecular basis of blood diseases. Philadelphia: W.B. Saunders, 1987:179–218.
7. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74: 652–6.
8. Veith R, Galanello R, Papayannopoulou T, Stamatoyannopoulos G. Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. N Engl J Med 1985; 313: 1571–5.
9. Dover GJ, Humphries RK, Moore JG, et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 1986; 67: 735–8.
10. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987; 69: 109–16.
11. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Induction of fetal hemoglobin in sickle cell patients by hydroxyurea: the N.I.H. experience. In: Stamatoyannopoulos G, Nienhuis AW, eds. Hemoglobin switching, part B: cellular and molecular mechanisms. Vol. 316B of Progress in clinical and biological research. New York: Alan R. Liss, 1989:281–93.
12. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988; 318: 96–9.
13. Rodgers GP, Schechter AN, Noguchi CT. Cell heterogeneity in sickle cell disease: quantitation of the erythrocyte density profile. J Lab Clin Med 1985; 106: 30–7.
14. Dover GJ, Boyer SH, Charache S, Heintzelman K. Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med 1978; 299: 1428–35.
15. Dover GJ, Chang VT, Boyer SH, Serjeant GR, Antonarakis S, Higgs DR. The cellular basis for different fetal hemoglobin levels among sickle cell individuals with two, three, and four alpha-globin genes. Blood 1987; 69: 341–4.
16. Noguchi CT, Dover GJ, Rodgers GP, et al. Alpha thalassemia changes erythrocyte heterogeneity in sickle cell disease. J Clin Invest 1985; 75: 1632–7.
17. Antonarakis SE, Boehm CD, Serjeant GR, Theisen CE, Dover GJ, Kazazian HH Jr. Origin of the beta S-globin gene in blacks: the contribution of recurrent mutation or gene conversion or both. Proc Natl Acad Sci U S A 1984; 81: 853–6.
18. Remington RD, Schork MA. Statistics with applications to the biological and health sciences. Englewood Cliffs, N.J.: Prentice-Hall, 1970.
19. Forsythe GE, Malcolm MA, Moler CB. Computer methods for mathematical computations. Englewood Cliffs, N.J.: Prentice-Hall, 1977.
20. Noguchi CT, Torchia DA, Schechter AN. The intracellular polymerization of sickle hemoglobin: effects of cell heterogeneity. J Clin Invest 1983; 72: 846–52.
21. Nagel RL, Fabry ME, Pagnier J, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa: the Senegal type and the Benin type. N Engl J Med 1985; 312: 880–4.
22. Miller BA, Olivieri N, Salameh M, et al. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. N Engl J Med 1987; 316: 244–50.
23. Bertles JF, Milner PF. Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia. J Clin Invest 1968; 47: 1731–41.
24. Letvin NL, Linch DC, Beardsley GP, Mclntyre KW, Nathan DG. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984; 310: 869–73.
25. Lavelle D, DeSimone J, Heller P, Zwiers D, Hall L. On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation. Blood 1986; 67: 1083–9.
26. Dover GJ, Humphries RK, Moore JG, et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 1986; 67: 735–8.
27. Humphries RK, Dover G, Young NS, et al. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest 1985; 75: 547–57.
28. Alter BP, Gilbert HS. The effect of hydroxyurea on hemoglobin F in patients with myeloproliferative syndromes. Blood 1985; 66: 373–9.
29. Burns ER, Reed LJ, Wenz B. Volumetric erythrocyte macrocytosis induced by hydroxyurea. Am J Clin Pathol 1986; 85: 337–41.
30. Brittenham GM, Schechter AN, Noguchi CT. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood 1985; 65: 183–9.
31. Dover GJ, Charache S. Stimulation of fetal hemoglobin production by hydroxyurea in sickle cell anemia. In: Stamatoyannopoulos G, Nienhuis AW, eds. Hemoglobin switching, part B: cellular and molecular mechanisms. Vol. 316B of Progress in clinical and biological research. New York: Alan R. Liss, 1989:295–306.
32. AI-Khatti A, Veith RW, Papayannopoulou T, Fritsch EF, Goldwasser E, Stamatoyannopoulos G. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med 1987; 317: 415–20.
33. McDonagh KT, Dover GJ, Donahue R, Nathan DG, Nienhuis AW. Manipulation of HbF production with hematopoietic growth factors. In: Stamatoyannopoulos G, Nienhuis AW, eds. Hemoglobin switching, part B: cellular and molecular mechanisms. Vol. 316B of Progress in clinical and biological research. New York: Alan R. Liss, 1989:307–15.